Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fully Collective Superradiant Lasing with Vanishing Sensitivity to Cavity Length Vibrations.

Physical review letters·2026
Same author

ICM 2025: New Technologies like Artificial Intelligence, Robotics, and Anti-Biofilm.

The Journal of arthroplasty·2025
Same author

Discrete Subdomains Establish Epigenetic Diversity in Subtelomeric Heterochromatin.

bioRxiv : the preprint server for biology·2025
Same author

Parametric modeling of deformable linear objects for robotic outfitting and maintenance of space systems.

Frontiers in robotics and AI·2025
Same author

Reply to the Letter to the Editor by Reynolds et al Regarding "Comparison of Postoperative Antibiotic Protocols for Pediatric Complicated Appendicitis: A Western Pediatric Surgery Research Consortium Study".

Journal of pediatric surgery·2025
Same author

Catheter ablation of atrial fibrillation in antiarrhythmic drug-naïve patients.

Heart rhythm·2025

Related Experiment Video

Updated: Jul 11, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Capecitabine induced vasospastic angina.

Stephanie Coughlin, Saugata Das, Justin Lee

    International Journal of Cardiology
    |September 28, 2007
    PubMed
    Summary

    Cardiotoxicity, a known side effect of intravenous 5-fluorouracil, is also observed with capecitabine. Patients with coronary artery disease should use this oral chemotherapy agent cautiously.

    Area of Science:

    • Oncology
    • Cardiology
    • Pharmacology

    Background:

    • Cardiotoxicity is a recognized adverse effect associated with intravenous 5-fluorouracil chemotherapy.
    • Capecitabine is an oral prodrug of 5-fluorouracil, increasingly used as an adjuvant chemotherapeutic agent.
    • The potential for capecitabine to induce cardiotoxicity, similar to its intravenous counterpart, warrants investigation.

    Purpose of the Study:

    • To report two cases of cardiotoxicity associated with capecitabine use.
    • To highlight the potential cardiovascular risks of oral capecitabine, particularly in vulnerable patient populations.
    • To emphasize the need for cautious use of capecitabine in patients with pre-existing coronary artery disease.

    Main Methods:

    • Presentation of two distinct case reports detailing patient treatment and adverse events.

    More Related Videos

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
    10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    Related Experiment Videos

    Last Updated: Jul 11, 2026

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
    04:48

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

    Published on: January 7, 2015

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
    10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

  • Clinical assessment and monitoring of cardiac function in patients receiving capecitabine.
  • Review of existing literature on 5-fluorouracil and capecitabine-induced cardiotoxicity.

    • Main Results:

    • Both reported cases exhibited cardiotoxic side effects consistent with those seen with intravenous 5-fluorouracil.
    • The observed cardiotoxicity manifested despite the oral administration route of capecitabine.
    • These findings suggest a shared mechanism of cardiac adverse events between 5-fluorouracil and capecitabine.

    Conclusions:

    • Capecitabine, an oral chemotherapeutic agent, can induce cardiotoxicity.
    • Patients with existing coronary artery disease are at increased risk for capecitabine-induced cardiotoxicity.
    • Careful patient selection and monitoring are crucial when prescribing capecitabine, especially in patients with cardiovascular risk factors.